Obstructive sleep apnoea in obesity: A review
SummaryObstructive sleep apnea is a common comorbidity that occurs in individuals with obesity. It classically manifests with excessive daytime sleepiness, resulting in reduced quality of life, workplace productivity, and an increased risk of motor vehicle accidents. Weight gain plays an important role in its pathogenesis through worsening upper airway collapsibility, and current treatment options are targeted towards mechanically overcoming upper airway obstruction and weight loss. Continuous positive airway pressure therapy remains the most widely prescribed treatment for obstructive sleep apnea but poor tolerance is a c...
Source: Clinical Obesity - February 29, 2024 Category: Eating Disorders & Weight Management Authors: Jian E. Tai,
Craig L. Phillips,
Brendon J. Yee,
Ronald R. Grunstein Tags: REVIEW Source Type: research
Identification of glucagon like peptide-1 (GLP-1) in mice stomach
This study marks the first report of GLP-1 production in the mouse stomach. Our findings suggest that gastric pre-proglucagon mRNA expression is regulated by a distinct mechanism compared to the L cells of the lower intestine.PMID:38417346 | DOI:10.1016/j.bbrc.2024.149708 (Source: Biochemical and Biophysical Research communications)
Source: Biochemical and Biophysical Research communications - February 28, 2024 Category: Biochemistry Authors: Manami Otsuka Jin Huang Toru Tanaka Ichiro Sakata Source Type: research
Identification of glucagon like peptide-1 (GLP-1) in mice stomach
This study marks the first report of GLP-1 production in the mouse stomach. Our findings suggest that gastric pre-proglucagon mRNA expression is regulated by a distinct mechanism compared to the L cells of the lower intestine.PMID:38417346 | DOI:10.1016/j.bbrc.2024.149708 (Source: Cell Research)
Source: Cell Research - February 28, 2024 Category: Cytology Authors: Manami Otsuka Jin Huang Toru Tanaka Ichiro Sakata Source Type: research
Identification of glucagon like peptide-1 (GLP-1) in mice stomach
This study marks the first report of GLP-1 production in the mouse stomach. Our findings suggest that gastric pre-proglucagon mRNA expression is regulated by a distinct mechanism compared to the L cells of the lower intestine.PMID:38417346 | DOI:10.1016/j.bbrc.2024.149708 (Source: Biochemical and Biophysical Research communications)
Source: Biochemical and Biophysical Research communications - February 28, 2024 Category: Biochemistry Authors: Manami Otsuka Jin Huang Toru Tanaka Ichiro Sakata Source Type: research
Metformin Effects on SHIP2, AMPKs and Gut Microbiota: Recent Updates on Pharmacology
CONCLUSION: In addition, new exciting mechanisms suggest the role of metformin in promoting beneficial gut microbiome and gut health; metformin regulates duodenal AMPK activation, incretin hormone secretion, and bile acid homeostasis to improve intestinal glucose absorption and utilization.PMID:38409699 | DOI:10.2174/0109298673289342240213040144 (Source: Current Medicinal Chemistry)
Source: Current Medicinal Chemistry - February 27, 2024 Category: Chemistry Authors: Priyanka Shivaprakash Narasimha M Beeraka Subba Rao V Madhunapantula Vladimir N Nikolenko Kanthesh M Basalingappa Source Type: research
Metformin Effects on SHIP2, AMPKs and Gut Microbiota: Recent Updates on Pharmacology
CONCLUSION: In addition, new exciting mechanisms suggest the role of metformin in promoting beneficial gut microbiome and gut health; metformin regulates duodenal AMPK activation, incretin hormone secretion, and bile acid homeostasis to improve intestinal glucose absorption and utilization.PMID:38409699 | DOI:10.2174/0109298673289342240213040144 (Source: Current Medicinal Chemistry)
Source: Current Medicinal Chemistry - February 27, 2024 Category: Chemistry Authors: Priyanka Shivaprakash Narasimha M Beeraka Subba Rao V Madhunapantula Vladimir N Nikolenko Kanthesh M Basalingappa Source Type: research
Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts' consensus statement
Front Endocrinol (Lausanne). 2024 Feb 9;15:1348990. doi: 10.3389/fendo.2024.1348990. eCollection 2024.ABSTRACTPasireotide is a somatostatin analogue for the treatment of acromegaly, a chronic condition caused by excess growth hormone. Despite the therapeutic benefits of pasireotide as a second-line treatment for inadequately controlled acromegaly, a major concern is its hyperglycemic side-effect. Here, we provide guidance on how to select appropriate patients with acromegaly for treatment with pasireotide. We summarize baseline characteristics of patients at high risk for pasireotide-associated hyperglycemia and recommend ...
Source: Cancer Control - February 26, 2024 Category: Cancer & Oncology Authors: Sylv ère Störmann Sebastian M Meyh öfer Jan B Groener Johanna Faust Katharina Schilbach Jochen Seufert Bruno Verg ès Source Type: research
Tirzepatide: A Review in Type 2 Diabetes
In conclusion, tirzepatide i s a valuable addition to the treatment options for T2DM. (Source: Drugs)
Source: Drugs - February 23, 2024 Category: Drugs & Pharmacology Source Type: research
Brain access of incretins and incretin receptor agonists to their central targets relevant for appetite suppression and weight loss
Am J Physiol Endocrinol Metab. 2024 Feb 21. doi: 10.1152/ajpendo.00250.2023. Online ahead of print.ABSTRACTIncretin-based pharmacotherapies provide novel efficient and safe therapeutic options to curb appetite and produce weight loss in obese patients. Delivered systemically, these molecules produce pleiotropic metabolic benefits, but the target sites mediating their weight-suppressive action are located within the brain. Recent research has increased our understanding of the neural circuits and behavioural mechanisms involved in the anorectic and metabolic consequences of glucagon-like peptide 1 (GLP-1)-based weight loss ...
Source: American Journal of Physiology. Endocrinology and Metabolism - February 21, 2024 Category: Physiology Authors: Sophie Buller Clemence Blouet Source Type: research
Brain access of incretins and incretin receptor agonists to their central targets relevant for appetite suppression and weight loss
Am J Physiol Endocrinol Metab. 2024 Feb 21. doi: 10.1152/ajpendo.00250.2023. Online ahead of print.ABSTRACTIncretin-based pharmacotherapies provide novel efficient and safe therapeutic options to curb appetite and produce weight loss in obese patients. Delivered systemically, these molecules produce pleiotropic metabolic benefits, but the target sites mediating their weight-suppressive action are located within the brain. Recent research has increased our understanding of the neural circuits and behavioural mechanisms involved in the anorectic and metabolic consequences of glucagon-like peptide 1 (GLP-1)-based weight loss ...
Source: Am J Physiol Endocri... - February 21, 2024 Category: Endocrinology Authors: Sophie Buller Clemence Blouet Source Type: research
Brain access of incretins and incretin receptor agonists to their central targets relevant for appetite suppression and weight loss
Am J Physiol Endocrinol Metab. 2024 Feb 21. doi: 10.1152/ajpendo.00250.2023. Online ahead of print.ABSTRACTIncretin-based pharmacotherapies provide novel efficient and safe therapeutic options to curb appetite and produce weight loss in obese patients. Delivered systemically, these molecules produce pleiotropic metabolic benefits, but the target sites mediating their weight-suppressive action are located within the brain. Recent research has increased our understanding of the neural circuits and behavioural mechanisms involved in the anorectic and metabolic consequences of glucagon-like peptide 1 (GLP-1)-based weight loss ...
Source: American Journal of Physiology. Endocrinology and Metabolism - February 21, 2024 Category: Physiology Authors: Sophie Buller Clemence Blouet Source Type: research
Brain access of incretins and incretin receptor agonists to their central targets relevant for appetite suppression and weight loss
Am J Physiol Endocrinol Metab. 2024 Feb 21. doi: 10.1152/ajpendo.00250.2023. Online ahead of print.ABSTRACTIncretin-based pharmacotherapies provide novel efficient and safe therapeutic options to curb appetite and produce weight loss in obese patients. Delivered systemically, these molecules produce pleiotropic metabolic benefits, but the target sites mediating their weight-suppressive action are located within the brain. Recent research has increased our understanding of the neural circuits and behavioural mechanisms involved in the anorectic and metabolic consequences of glucagon-like peptide 1 (GLP-1)-based weight loss ...
Source: Am J Physiol Endocri... - February 21, 2024 Category: Endocrinology Authors: Sophie Buller Clemence Blouet Source Type: research
Brain access of incretins and incretin receptor agonists to their central targets relevant for appetite suppression and weight loss
Am J Physiol Endocrinol Metab. 2024 Feb 21. doi: 10.1152/ajpendo.00250.2023. Online ahead of print.ABSTRACTIncretin-based pharmacotherapies provide novel efficient and safe therapeutic options to curb appetite and produce weight loss in obese patients. Delivered systemically, these molecules produce pleiotropic metabolic benefits, but the target sites mediating their weight-suppressive action are located within the brain. Recent research has increased our understanding of the neural circuits and behavioural mechanisms involved in the anorectic and metabolic consequences of glucagon-like peptide 1 (GLP-1)-based weight loss ...
Source: American Journal of Physiology. Endocrinology and Metabolism - February 21, 2024 Category: Physiology Authors: Sophie Buller Clemence Blouet Source Type: research
Brain access of incretins and incretin receptor agonists to their central targets relevant for appetite suppression and weight loss
Am J Physiol Endocrinol Metab. 2024 Feb 21. doi: 10.1152/ajpendo.00250.2023. Online ahead of print.ABSTRACTIncretin-based pharmacotherapies provide novel efficient and safe therapeutic options to curb appetite and produce weight loss in obese patients. Delivered systemically, these molecules produce pleiotropic metabolic benefits, but the target sites mediating their weight-suppressive action are located within the brain. Recent research has increased our understanding of the neural circuits and behavioural mechanisms involved in the anorectic and metabolic consequences of glucagon-like peptide 1 (GLP-1)-based weight loss ...
Source: Am J Physiol Endocri... - February 21, 2024 Category: Endocrinology Authors: Sophie Buller Clemence Blouet Source Type: research
